Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05269316 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
A Phase 1 study of Solid Tumor and Advanced Solid Tumor, sponsored by Impact Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
- 8
- Study locations
NCT05269316 is a Phase 1 study of Solid Tumor and Advanced Solid Tumor that is actively recruiting participants, run by Impact Therapeutics. The registered enrollment target is 61 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (72% lower). The trial reports 8 study locations across 7 states.
The verdict
NCT05269316, a Phase 1 study of Solid Tumor and Advanced Solid Tumor, is actively recruiting participants, sponsored by Impact Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of IMP9064 as monotherapy or in combination with PARP inhibitor Senaparib in patients with advanced solid tumors
Conditions Studied
Interventions
- DRUG IMP9064
Study Locations (8)
Other
- Linear Clinical Research Limited - Nedlands
- National Taiwan University Hospital - Taipei
New Jersey
- Hackensack University Medical Center PARTNER - Hackensack
New York
- Mount Sinai - New York
South Carolina
- Greenville Hospital System University Medical Center (ITOR) - Greenville
Texas
- Mary Crowley Cancer Research Centers - Dallas
New South Wales
- Blacktown Hospital - Blacktown
Beijing Municipality
- Beijing Cancer Hospital - Beijing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2022-02-11 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05269316
The ClinicalTrials.gov registry entry for NCT05269316 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (72% lower). The listed sponsor is Impact Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which IMP9064 is the first listed.
NCT05269316 reports 8 study locations spanning 7 distinct geographic areas - top geographies include Other, New Jersey, New York.
Frequently Asked Questions
What is clinical trial NCT05269316 about?
NCT05269316 is a clinical study titled "Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors". This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of IMP9064 as monotherapy or in combination with PARP inhibitor Senaparib in patients with advanced solid tumors
What is the current status of trial NCT05269316?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2022-02-11. Estimated completion is 2026-12-31.
What conditions does trial NCT05269316 study?
This clinical trial studies the following conditions: Solid Tumor, Advanced Solid Tumor.
What interventions are being tested in trial NCT05269316?
The interventions under investigation include: IMP9064 (DRUG).
Who is sponsoring clinical trial NCT05269316?
This trial is sponsored by Impact Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05269316 being conducted?
This trial has 8 study locations across New Jersey, New York, South Carolina, Texas, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.